Please login to the form below

Not currently logged in
Email:
Password:

Ryzodeg

This page shows the latest Ryzodeg news and features for those working in and with pharma, biotech and healthcare.

Novo seeks to strengthen Tresiba label in US

Novo seeks to strengthen Tresiba label in US

Interim results from the 7, 500-patient DEVOTE study were instrumental in allowing Novo to get FDA approval for Tresiba and combination drug Ryzodeg in 2015, after being knocked back by

Latest news

  • Novo Nordisk's Tresiba gaining ground in basal insulin market Novo Nordisk's Tresiba gaining ground in basal insulin market

    Nevertheless, the strong sales performance for Tresiba and other new insulin products - such as combination products Ryzodeg (insulin degludec/insulin aspart) and Xultophy (insulin degludec/liraglutide) - helped Novo Nordisk post a

  • Tresiba safer than insulin glargine, says Novo Nordisk Tresiba safer than insulin glargine, says Novo Nordisk

    Last October however the Danish drugmaker finally won US approval for Tresiba and combination product Ryzodeg (insulin degludec and insulin aspart), prompting analysts at Sydbank to increase their peak sales predictions

  • Novo Nordisk finally bags insulin degludec approval in US Novo Nordisk finally bags insulin degludec approval in US

    Ryzodeg, two drugs expected to consolidate its position as the leading diabetes company. ... Earlier this year however Novo Nordisk decided to refile Tresiba and Ryzodeg on the strength of interim data from the outcomes trial, called DEVOTE.

  • Novo brings Xultophy to third European market Novo brings Xultophy to third European market

    US regulators dealt the company a major blow in February 2013 when marketing applications for Tresiba and Ryzodeg, which combines Tresiba with Novo's Novolog (insulin aspart), were rejected.

  • Novo Nordisk opens insulin facility in Russia Novo Nordisk opens insulin facility in Russia

    Last month, the firm revealed plans to resubmit its FDA marketing applications for diabetes therapies Tresiba and Ryzodeg after being rejected two years ago, with the regulatory body beginning its revaluation

More from news
Approximately 6 fully matching, plus 14 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Six Degrees Medical Consulting

For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...

Latest intelligence

01 PME-APR21 Cover.jpg
Virtual congresses: video thrilled the cardio tsar
Chris Ross explores the key learnings from a year of virtual congresses...
When Will We Be Back To Normal?
The definitive question of 2021, whether you’re a homeschooling parent, a homebound professional, a wanderer with nowhere to go… or all three at once....
How to tell your healthcare story.
Healthcare research is not a simple story and the people in charge of those moments need to be careful about the story that they tell....

Infographics